§-31 (MTP-131)

What is SS-31?

SS-31 (known chemically as Elamipretide, MTP-131, or Bendavia) is a cell-permeable, mitochondria-targeted tetrapeptide belonging to the Szeto-Schiller (SS) peptide family. Composed of alternating aromatic and basic amino acids (D-Arg-Dmt-Lys-Phe-NH2), this small peptide bypasses traditional carrier-mediated transport to penetrate cellular membranes rapidly and concentrate within the inner mitochondrial membrane (IMM). Researchers investigate SS-31 for its unique ability to bind selectively to cardiolipin, stabilizing mitochondrial structural architecture, optimizing ATP production, and mitigating electron leak during states of heavy cellular stress.

For laboratory and in vitro evaluation, researchers often choose to buy SS-31 in high-purity lyophilized form. Reconstituted solutions can be securely prepared using standard laboratory buffers or specialized reconstitution solution to maintain peptide distribution and prevent premature structural oxidation during live cell screening assays.

Chemical and Molecular Data

What are the Mechanisms of Action?

The biochemical pathways and cellular targets of SS-31 include:

• Cardiolipin Stabilization: Research demonstrates that the basic amino acid residues of SS-31 interact electrostatically and hydrophobically with cardiolipin, a unique phospholipid located exclusively on the inner mitochondrial membrane. This interaction creates a protective shield over cardiolipin, preventing it from undergoing lipid peroxidation mediated by disrupted cytochrome c complexes.
• Cristae Architecture Preservation: By safeguarding cardiolipin from oxidative degradation, SS-31 maintains optimal curvature and structure of the mitochondrial cristae. This structural preservation anchors the electron transport chain components into tight supercomplexes, optimizing overall spatial efficiency.
• Mitochondrial Electron Coupling: Studies indicate that the compound facilitates smoother electron flow through Complex I, II, III, and IV to Complex V (ATP Synthase). By optimizing this transport, it drastically reduces electron leak, suppressing the formation of intracellular superoxide radicals right at the primary site of generation.

What are the Clinical & Preclinical Trials on SS-31?

When evaluating research efficacy and published experimental literature for SS-31:

• Ischemia-Reperfusion Injury Mitigation: Preclinical investigations evaluating sudden oxygen deprivation models demonstrated that administration of SS-31 prior to tissue reperfusion significantly protects structural cell boundaries. The peptide limits outer membrane permeability and prevents sudden microvascular collapse by maintaining baseline ATP production through severe oxidative stress events.
• Cardiomyocyte Energetic Rebalancing: Advanced trials focusing on heart failure and renal tissue degradation confirm that regular SS-31 administration stabilizes metabolic output within target tissue samples, reducing pathological fibrosis and reversing structural mitochondrial fragmentation.
• Safety & Cellular Dynamics Profile: Across laboratory safety evaluations, SS-31 exhibits an exceptional target-specific safety profile. Because its binding is completely dependent on the presence of highly curved cardiolipin structures, it showcases no toxic cross-reactivity with standard non-mitochondrial cellular bilayers.

How does SS-31 compare to other compounds?

To evaluate target specificity, mitochondrial mechanics, and tissue-remodeling cascades, researchers compare SS-31 against alternative structural bioenergetic modulators and mitochondrial-derived peptides: